## COMPOUNDS OF THE

## SAFRAMYCIN-ECTEINASCIDIN SERIES, USES, AND SYNTHESIS THEREOF

## Abstract of the Invention

Compounds of the saframycin-ecteinascidin series with cytotoxic properties having the following general formula, their uses and synthesis, are disclosed:

$$R_{10}$$
 $R_{10}$ 
 $R_{10}$ 
 $R_{10}$ 
 $R_{10}$ 
 $R_{11}$ 
 $R_{10}$ 
 $R_{11}$ 
 $R_{10}$ 
 $R_{11}$ 
 $R_{10}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{11}$ 
 $R$ 

wherein  $R_1$  and  $R_4$  is H, a  $C_1$  to  $C_4$  alkyl group, or an acyl group;

wherein  $R_2$  is an ether, ester, amide, or a phthalimide group; wherein  $R_3$  is =0, OH, an ether group, an acyl group such as OC(O)Me, OC(O)Bn and OC(O)Et, or a sulfide group; wherein  $R_5$  is H, halogen, OH, an ether group, an acyl group, or an amide group; wherein  $R_6$  is =0, OH, OCH<sub>3</sub>, CN, or an acyloxy group; wherein  $R_7$ , is =0, OH, halogen, an ether group, or an acyl group; wherein  $R_8$  and  $R_9$  are independently H, CH<sub>3</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, halogen such as Br and F, or  $R_8$  and  $R_9$  are joined together as a methylenedioxy group, or other five or six membered ring; wherein  $R_{10}$  and  $R_{11}$  are independently CH<sub>3</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, SCH<sub>3</sub>, or SC<sub>2</sub>H<sub>5</sub>; wherein  $R_{12}$  is H, a C<sub>1</sub> to C<sub>4</sub> alkyl group, or an

acyl group; and wherein the chiral center marked  $\ast$  has the R or the S configuration.